Andrew Woodhead
39 works · 2,045 citations · h-index 11
Top works
- Recent Developments in Fragment-Based Drug Discovery
- Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
- Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency
- Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
- From fragment to clinical candidate—a historical perspective
- Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
- Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
- Fragment-to-Lead Medicinal Chemistry Publications in 2022
- Fragment-to-Lead Medicinal Chemistry Publications in 2021
- Fragment-to-Lead Medicinal Chemistry Publications in 2023
- Structural biology and anticancer drug design
- Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
- Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
- Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.
- Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function
- ChemInform Abstract: Recent Developments in Fragment‐Based Drug Discovery
- Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design
- 117 Identification of novel cyclin dependent kinase 1/2 inhibitors using fragment based high-throughput X-ray crystallography and structure based drug design
- Discovery of AT26893, a novel allosteric inhibitor of the regulation of HCV NS3/4a protein function
- Abstract A110: Identifying sensitive patient populations for CDK7 inhibitors using cell panel screens and bioinformatic approaches